{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T12:21:07Z","timestamp":1754482867486,"version":"3.41.2"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R41AI149803-01A1"],"award-info":[{"award-number":["1R41AI149803-01A1"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Mutacin 1140 (Mu1140) is a potent antibiotic against Gram-positive bacteria, such as <jats:italic>Staphylococcus aureus<\/jats:italic>. The antibiotic is produced by the oral bacterium <jats:italic>Streptococcus mutans<\/jats:italic> and is a member of the epidermin family of type AI lantibiotics. The antibiotic exerts its inhibitory activity by binding to the cell wall precursor lipid II, blocking cell wall synthesis, and by disrupting bacterial membranes. In previous studies, the novel K2A and R13A analogs of Mu1140 have been identified to have superior pharmacokinetic properties compared to native Mu1140. In this study, the use of a combined formulation of the Mu1140 K2A and R13A analogs was shown to be more effective at treating MRSA bacteremia than the native Mu1140 or vancomycin. The analogs were also shown to be effective in treating an MRSA skin infection. The use of K2A and R13A analogs may provide a future alternative for treating serious Gram-positive bacterial infections. In a previous study, the Mu1140 analogs were shown to have significantly longer drug clearance times, leading to higher plasma concentrations over time. These properties warranted further testing to determine whether the analogs are effective for the treatment of systemic MRSA and acute skin infections. In this study, Mu1140 analogs were shown to be more effective than currently available treatments for systemic and skin MRSA infections. Further, the study clearly shows that the new analogs are superior to native Mu1140 for the treatment of a systemic MRSA infection. These findings support continued drug product development efforts using the K2A and R13A Mu1140 analogs, and that these analogs may ameliorate the outcome of serious bacterial infections.<\/jats:p>","DOI":"10.3389\/fmicb.2022.1067410","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:31:59Z","timestamp":1671006719000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of analogs of mutacin 1140 in systemic and cutaneous methicillin-resistant Staphylococcus aureus infection models in mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Min","family":"Ju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thushinari","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nopakorn","family":"Hansanant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"McKinley","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Cothrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew Riley","family":"Buhrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/13543784.2022.2040015","article-title":"Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials","volume":"31","author":"Burgin","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e0118791","DOI":"10.1371\/journal.pone.0118791","article-title":"Vancomycin tolerant, methicillin-resistant Staphylococcus aureus reveals the effects of vancomycin on cell wall thickening","volume":"10","author":"C\u00e1zares-Dom\u00ednguez","year":"2015","journal-title":"PLoS One"},{"volume-title":"Antibiotic Resistance Threats in the United States","year":"2019","key":"ref3"},{"volume-title":"2020 national and state healthcare-associated infections progress report [online]","year":"","key":"ref4"},{"volume-title":"CDC partners estimate healthcare cost of antibiotic-resistant infections [online]","year":"","key":"ref5"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1128\/AEM.00704-13","article-title":"Site-directed mutations in the lanthipeptide mutacin 1140","volume":"79","author":"Chen","year":"2013","journal-title":"Appl. Environ. Microbiol."},{"volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically","year":"2018","key":"ref7"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.2337\/db16-0565","article-title":"Topical prostaglandin E analog restores defective dendritic cell\u2013mediated Th17 host defense against methicillin-resistant Staphylococcus aureus in the skin of diabetic mice","volume":"65","author":"Dejani","year":"2016","journal-title":"Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/adc.2003.019695","article-title":"Fusidic acid resistance in Staphylococcus aureus","volume":"89","author":"Dobie","year":"2004","journal-title":"Arch. Dis. Child."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e00668","DOI":"10.1128\/AEM.00668-17","article-title":"Carboxyl analogue of mutacin 1140, a scaffold for lead antibacterial discovery","volume":"83","author":"Escano","year":"2017","journal-title":"Appl. Environ. Microbiol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1128\/JB.02531-14","article-title":"Biosynthesis and transport of the lantibiotic mutacin 1140 produced by Streptococcus mutans","volume":"197","author":"Escano","year":"2015","journal-title":"J. Bacteriol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e01626","DOI":"10.1128\/AAC.01626-18","article-title":"Efficacious analogs of the lantibiotic mutacin 1140 against a systemic methicillin-resistant Staphylococcus aureus infection","volume":"62","author":"Geng","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e00830","DOI":"10.1128\/AEM.00830-18","article-title":"Modifying the lantibiotic mutacin 1140 for increased yield, activity, and stability","volume":"84","author":"Geng","year":"2018","journal-title":"Appl. Environ. Microbiol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1128\/AAC.01003-12","article-title":"In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice","volume":"57","author":"Guo","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-021-00943-6","article-title":"The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis","volume":"10","author":"Hajikhani","year":"2021","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1126\/science.1129818","article-title":"An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II","volume":"313","author":"Hasper","year":"2006","journal-title":"Science"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/antibiotics11020182","article-title":"Antibiotic discovery and resistance: the chase and the race","volume":"11","author":"Iskandar","year":"2022","journal-title":"Antibiotics"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1128\/AAC.49.8.3435-3441.2005","article-title":"Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and streptococcus pyogenes","volume":"49","author":"Kugelberg","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/S1473-3099(20)30629-0","article-title":"New fund stimulates the ailing antibiotic pipeline","volume":"20","author":"McCall","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.18502\/rmm.v6i4.4802","article-title":"Antimicrobial effect of multilayered carbon nanotubes on multi-drug-resistant Pseudomonas aeruginosa","volume":"6","author":"Mousavi","year":"2018","journal-title":"Res. Mol. Med."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.34172\/ajcmi.2020.15","article-title":"Re-construction of co-expression network of genes involved in bacterial cell wall synthesis and their role in penicillin resistance","volume":"7","author":"Shiri","year":"2020","journal-title":"Avicenna J. Clin. Microbiol. Infect."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e02062","DOI":"10.1128\/AAC.02062-19","article-title":"New evidence and insights on dalbavancin and wound healing in a mouse model of skin infection","volume":"64","author":"Simonetti","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1021\/bi701262z","article-title":"Elucidation of the antimicrobial mechanism of mutacin 1140","volume":"47","author":"Smith","year":"2008","journal-title":"Biochemistry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"6810","DOI":"10.1046\/j.1432-1033.2000.01777.x","article-title":"Covalent structure of mutacin 1140 and a novel method for the rapid identification of lantibiotics","volume":"267","author":"Smith","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"10372","DOI":"10.1021\/bi034490u","article-title":"Structure and dynamics of the lantibiotic mutacin 1140","volume":"42","author":"Smith","year":"2003","journal-title":"Biochemistry"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.1067410\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T08:32:12Z","timestamp":1671006732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2022.1067410\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":27,"alternative-id":["10.3389\/fmicb.2022.1067410"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2022.1067410","relation":{},"ISSN":["1664-302X"],"issn-type":[{"type":"electronic","value":"1664-302X"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1067410"}}